Content about Novo Nordisk

March 28, 2014

Novo Nordisk on Friday launched "Cities Changing Diabetes," a new partnership program to fight the urban diabetes challenge.

BAGSVAERD, Denmark — Novo Nordisk on Friday launched "Cities Changing Diabetes," a new partnership program to fight the urban diabetes challenge. The "Cities Changing Diabetes"program will first be launched in Mexico City, with other cities in North America, Europe and Asia soon to follow.

March 6, 2014

Study results announced Thursday by Novo Nordisk and collaborative partners found that participation in diabetes education is associated with a greater sense of well-being and the ability to self-manage diabetes.

LIVERPOOL, England — Study results announced Thursday by Novo Nordisk and collaborative partners found that participation in diabetes education is associated with a greater sense of well-being and the ability to self-manage diabetes.

However, more than three-quarters of people with diabetes in the United Kingdom (78%) have never attended a diabetes education program, and family members are rarely included (79%). Additionally, only 14% of healthcare professionals say that all their patients with diabetes are offered structured diabetes education classes.

January 31, 2014

Global healthcare company Novo Nordisk announced the promotion of Eddie Williams to SVP biopharmaceuticals, effective Feb. 1, 2014.

PRINCETON, N.J. — Global healthcare company Novo Nordisk announced the promotion of Eddie Williams to SVP biopharmaceuticals, effective Feb. 1, 2014.

January 23, 2014

Mylan announced that its U.S.-based subsidiary has launched repaglinide tablets, a generic version of Novo Nordisk's Prandin.

PITTSBURGH — Mylan on Thursday announced that its subsidiary has launched repaglinide tablets, a generic version of Novo Nordisk's Prandin. The drug is used to improve glycemic control in adults with Type 2 diabetes mellitus.

Repaglinide tablets in 0.5 mg, 1 mg and 2 mg had sales in the United States of approximately $212.95 million for the 12 months ending Sept. 30, 2013, according to IMS Health.

 

January 21, 2014

With the role of social media rapidly expanding, nearly half of pharmaceutical manufacturers are now actively using this channel to engage with patients on healthcare-related topics, according to a new report by the IMS Institute for Healthcare Informatics.

PARSIPPANY, N.J. — With the role of social media rapidly expanding, nearly half of pharmaceutical manufacturers are now actively using this channel to engage with patients on healthcare-related topics, according to a new report released Tuesday by the IMS Institute for Healthcare Informatics. 

January 21, 2014

Novo Nordisk has launched a new insulin pen designed for children with diabetes.

NEW YORK — Novo Nordisk has launched a new insulin pen designed for children with diabetes.

The new NovoPen Echo is the first and only prefilled pen device in the United States that allows for half-unit dosing in combination with a memory function, the company said.

December 23, 2013

The Food and Drug Administration has approved a new treatment made by Danish drug maker Novo Nordiskfor a rare, genetic bleeding disorder, the agency said Monday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment made by Danish drug maker Novo Nordiskfor a rare, genetic bleeding disorder, the agency said Monday.

December 12, 2013

Diabetes organizations in several cities are getting a boost in funding from a Danish drug maker that specializes in developing treatments for the disease.

NEW YORK — Diabetes organizations in several cities are getting a boost in funding from a Danish drug maker that specializes in developing treatments for the disease.

Novo Nordisk said it would provide funding to groups in Seattle; Portland, Ore.; and Rochester, Minn., as part of the Novo Nordisk Community Care initiative. The initiative provides funding to nonprofits that support educational programs for people with Type 2 diabetes.

November 1, 2013

The Food and Drug Administration has approved two new insulin pens made by Novo Nordisk, the Danish drug maker said Friday.

PLAINSBORO, N.J. — The Food and Drug Administration has approved two new insulin pens made by Novo Nordisk, the Danish drug maker said Friday.

Novo Nordisk announced the FDA approval of Novolog FlexTouch (insulin aspart [rDNA origin]) and Levemir FlexTouch (insulin detemir [rDNA origin]).

October 17, 2013

The Food and Drug Administration has approved a new drug made by Novo Nordisk for treating hemophilia A, the Danish drug maker said.

BAGSVÆRD, Denmark — The Food and Drug Administration has approved a new drug made by Novo Nordisk for treating hemophilia A, the Danish drug maker said.

Novo Nordisk announced the approval of Novoeight (turoctocog alfa), a recombinant coagulation factor VIII, for adults and children with hemophilia, a disease caused by factor VIII deficiency that results in uncontrollable bleeding.

August 21, 2013

The Food and Drug Administration has given the green light to an insulin pen made by Novo Nordisk for half-unit dosing, the drug maker said Wednesday.

PLAINSBORO, N.J. — The Food and Drug Administration has given the green light to an insulin pen made by Novo Nordisk for half-unit dosing, the drug maker said Wednesday.

August 2, 2013

Novo Nordisk is offering $80,000 to diabetes-education programs in a Minnesota city, the Danish drug maker said Friday.

ROCHESTER, Minn. — Novo Nordisk is offering $80,000 to diabetes-education programs in a Minnesota city, the Danish drug maker said Friday.

The company said it would give the money to support local organizations that educate people living with Type 2 diabetes in Rochester, Minn.

July 19, 2013

Perrigo announced the tentative approval for repaglinide tablets, a generic version of Novo Nordisk's Prandin, used to treat Type 2 diabetes.

ALLEGAN, Mich. – The Food and Drug Administration has given tentative approval to a generic diabetes drug.

Perrigo Co. announced the tentative approval for repaglinide tablets, a generic version of Novo Nordisk's Prandin, used to treat Type 2 diabetes.

July 12, 2013

The Indian generic drug maker announced the approval of repaglinide tablets in the 1-mg and 2-mg strengths, which are used in combination with diet and exercise to improve blood-sugar control in patients with Type 2 diabetes.

MUMBAI, India — The Food and Drug Administration has approved a generic diabetes drug made by Sun Pharmaceutical Industries, Sun said Friday.

The Indian generic drug maker announced the approval of repaglinide tablets in the 1-mg and 2-mg strengths, which are used in combination with diet and exercise to improve blood-sugar control in patients with Type 2 diabetes.

June 27, 2013

An athletic team consisting entirely of people with diabetes will take part in several professional competitions and speaking events in Canada.

MISSISSAUGA, Ontario — An athletic team consisting entirely of people with diabetes will take part in several professional competitions and speaking events in Canada.

Team Novo Nordisk, organized by the Danish drug maker, includes 17 professional bike riders from 10 countries, including winners and podium finishers from professional races. The team will take part in the Tour de Beauce in Quebec, with three cyclists, and will compete in BC Superweek in British Columbia, as well as other competitions around the country.

June 27, 2013

Target has ended its relationship with celebrity chef Paula Deen following reports that she used racial slurs, according to published reports.

NEW YORK — Target has ended its relationship with celebrity chef Paula Deen following reports that she used racial slurs, according to published reports.

The Associated Press reported that the Minneapolis-based mass merchandise chain would not replenish its inventory of Paula Deen-branded cookware in its stores or online once the merchandise sold out. Walmart has made a similar announcement.

April 5, 2013

Novo Nordisk has launched a diabetes awareness sweepstakes in which the winners get a free trip to the 2013 IndyCar finale, the Danish drug maker said.

BIRMINGHAM, Ala. — Novo Nordisk has launched a diabetes awareness sweepstakes in which the winners get a free trip to the 2013 IndyCar finale, the Danish drug maker said Friday.

The company announced that it had hired IZOD IndyCar Series Charlie Kimball as spokesman for its Race with Insulin contest. Kimball, the first licensed driver with diabetes to race at the highest level of the series, was diagnosed with the disease during a routine doctor visit in 2007 while racing in Europe and is a user of Novo Nordisk's NovoLog (insulin aspart [rDNA origin]).

March 22, 2013

A drug made by Novo Nordisk for Type 2 diabetes produced a 6% loss of weight in a trial of the drug in obese patients, the company said.

BAGSVÆRD, Denmark — A drug made by Novo Nordisk for Type 2 diabetes produced a 6% loss of weight in a trial of the drug in obese patients, the company said.

The Danish drug maker announced results of a 56-week phase-3 trial to investigate the potential of Victoza (liraglutide) to produce and maintain weight loss in overweight and obese patients with Type 2 diabetes.

February 19, 2013

Mylan and Biocon have a deal to develop and sell generic insulin-analog products for diabetes, Mylan said.

PITTSBURGH — Mylan and Biocon have a deal to develop and sell generic insulin-analog products for diabetes, Mylan said.

Under the deal, Mylan will have the rights to develop and market Biocon's Glargine, Lispro and Aspart, respectively generic versions of Sanofi's Lantus, Eli Lilly's Humalog and Novo Nordisk's NovoLog.

February 11, 2013

The Food and Drug Administration declined to approve two insulin products made by Danish drug maker Novo Nordisk, the company said Sunday.

BAGSVÆRD, Denmark — The Food and Drug Administration declined to approve two insulin products made by Danish drug maker Novo Nordisk, the company said Sunday.

Novo Nordisk said it received complete response letters from the FDA for Tresiba (insulin degludec) and Ryzodeg (insulin degludec and insulin aspart). The FDA issues a complete response letter when it has finished reviewing an application for a drug, but determines that the application can't be approved in its current form.

January 17, 2013

Fortune magazine has released its list of the 100 best companies to work for this year, and a number of retailers and suppliers made the cut.

NEW YORK — Fortune magazine has released its list of the 100 best companies to work for this year, and a number of retailers and suppliers made the cut.

Among retailers, Wegman's Food Markets came in at fifth place, with 8.3% job growth. Nugget Market, a supermarket chain based in Sacramento, Calif., ranked 37th; Whole Foods ranked 71st; and Publix Super Markets ranked 77th.

Among suppliers, Millennium: The Takeda Oncology Company, ranked 20th; Genentech ranked 36th; and Novo Nordisk ranked 48th. Confectionary manufacturer Mars ranked 95th.

January 4, 2013

Novo Nordisk has appointed Curtis Oltmans as its corporate VP and general counsel for legal and quality affairs, the company said Friday.

PRINCETON, N.J. — Novo Nordisk has appointed Curtis Oltmans as its corporate VP and general counsel for legal and quality affairs, the company said Friday.

In the new role, for which he will also join the company's U.S. executive team, Oltmans will be handle issues like law, quality, intellectual property, grants and philanthropy for the Danish drug maker's North American business.

December 5, 2012

Drug maker Novo Nordisk is creating what it calls the world's first all-diabetes professional cycling team, the company said.

BAGSVÆRD, Denmark — Drug maker Novo Nordisk is creating what it calls the world's first all-diabetes professional cycling team, the company said.

The Danish pharmaceutical manufacturer announced plans to create Team Novo Nordisk, a global team with more than 100 cyclists, triathletes and runners, all of whom have diabetes.

November 28, 2012

As New York City enjoyed the first snowfall of the winter season, industry leaders gathered for the 14th annual Industry Issues Summit to discuss the top issues and trends impacting the industry, including the importance of seizing “whitespaces.”

NEW YORK — As New York City enjoyed the first snowfall of the winter season, industry leaders gathered for the 14th annual Industry Issues Summit to discuss the top issues and trends impacting the industry, including the importance of seizing “whitespaces.”

The all-day event was held on Tuesday at the New York Athletic Club, located just across the street from Central Park.

November 28, 2012

Novo Nordisk has launched a mobile app for hemophilia patients, the drug maker said.

PRINCETON, N.J. — Novo Nordisk has launched a mobile app for hemophilia patients, the drug maker said.

HemaGo — available for iPhone, iPad and Android devices — is designed to track hemophilia treatment, bleeding episodes and life events, helping people with the condition and their caregivers monitor the details of treatment, including medications, dosing, bleeding information and the disease's effects on life events.